Cardiff Oncology (NASDAQ:CRDF – Get Free Report) and Dianthus Therapeutics (NASDAQ:DNTH – Get Free Report) are both healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, earnings, dividends, profitability, valuation, risk and analyst recommendations.
Earnings & Valuation
This table compares Cardiff Oncology and Dianthus Therapeutics”s revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Cardiff Oncology | $590,000.00 | 118.35 | -$45.85 million | ($0.60) | -1.50 |
| Dianthus Therapeutics | $2.04 million | 2,211.07 | -$162.34 million | ($4.15) | -19.83 |
Cardiff Oncology has higher earnings, but lower revenue than Dianthus Therapeutics. Dianthus Therapeutics is trading at a lower price-to-earnings ratio than Cardiff Oncology, indicating that it is currently the more affordable of the two stocks.
Volatility & Risk
Cardiff Oncology has a beta of 1.42, meaning that its share price is 42% more volatile than the S&P 500. Comparatively, Dianthus Therapeutics has a beta of 1.35, meaning that its share price is 35% more volatile than the S&P 500.
Institutional and Insider Ownership
16.3% of Cardiff Oncology shares are held by institutional investors. Comparatively, 47.5% of Dianthus Therapeutics shares are held by institutional investors. 8.8% of Cardiff Oncology shares are held by insiders. Comparatively, 3.0% of Dianthus Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
Profitability
This table compares Cardiff Oncology and Dianthus Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Cardiff Oncology | -7,885.43% | -103.10% | -75.52% |
| Dianthus Therapeutics | -10,096.95% | -22.53% | -21.55% |
Analyst Ratings
This is a summary of recent ratings and price targets for Cardiff Oncology and Dianthus Therapeutics, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Cardiff Oncology | 1 | 3 | 3 | 0 | 2.29 |
| Dianthus Therapeutics | 1 | 0 | 13 | 2 | 3.00 |
Cardiff Oncology currently has a consensus target price of $7.50, indicating a potential upside of 735.56%. Dianthus Therapeutics has a consensus target price of $128.54, indicating a potential upside of 56.16%. Given Cardiff Oncology’s higher probable upside, equities research analysts clearly believe Cardiff Oncology is more favorable than Dianthus Therapeutics.
Summary
Dianthus Therapeutics beats Cardiff Oncology on 8 of the 15 factors compared between the two stocks.
About Cardiff Oncology
Cardiff Oncology, Inc., a clinical-stage biotechnology company, develops novel therapies to treat various cancers in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor to treatment a range of solid tumor cancers and KRAS/NRAS-mutated metastatic colorectal and metastatic pancreatic cancer, as well as investigator-initiated trials in triple negative breast cancer and small cell lung cancer; and TROV-054 is a Phase 1b/2 for FOLFIRI and bevacizumab. The company primarily serves pharmaceutical manufacturers. The company was formerly known as Trovagene, Inc. and changed its name to Cardiff Oncology, Inc. in May 2012. Cardiff Oncology, Inc. was incorporated in 1999 and is headquartered in San Diego, California.
About Dianthus Therapeutics
Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc. was founded in 2019 and is headquartered in New York, New York.
Receive News & Ratings for Cardiff Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cardiff Oncology and related companies with MarketBeat.com's FREE daily email newsletter.
